A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524181-26-00

Enrollment

Registered

2026-05-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/refractory multiple myeloma

Brief summary

Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)

Detailed description

Duration of response, Complete response (CR) rate, Time to response, Progression free survival, Overall survival, Frequency and severity of adverse events (AEs); serious AEs (SAEs); AEs leading to treatment interruption, reduction, or discontinuation; and deaths, Plasma concentrations of cemsidomide

Interventions

DRUGCemsidomide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)	—

Secondary

Measure	Time frame
Duration of response, Complete response (CR) rate, Time to response, Progression free survival, Overall survival, Frequency and severity of adverse events (AEs); serious AEs (SAEs); AEs leading to treatment interruption, reduction, or discontinuation; and deaths, Plasma concentrations of cemsidomide	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 27, 2026